Exocrine Pancreatic Insufficiency Market: Global Industry Analysis, Trends, Market Size, and, Forecasts up to 2023

1
Exocrine Pancreatic Insufficiency Market Global
Industry Analysis, Trends, Market Size, and,
Forecasts up to 2023
2
The report on Exocrine Pancreatic Insufficiency
Market by Infinium Global Research analyzes over
the period of 2017 to 2023. This report also
provides detailed qualitative and quantitative
analyses of the market dynamics, market size and
future trends in Global Exocrine Pancreatic
Insufficiency Market. It will help a lot of
decision makers to develop strategies and find
new opportunities in the Global Exocrine
Pancreatic Insufficiency Market. Exocrine
Pancreatic Insufficiency (EPI) is a serious
digestive problem and caused by improper
digestion, and exocrine pancreatic
insufficiency. It is a kind of a chronic disease
caused by deficiency in pancreatic enzyme.
Global revenue of exocrine pancreatic
insufficiency market, was valued at more than USD
700 million in 2015, and is projected to surpass
USD X.X Billion by 2023. Furthermore, the global
exocrine pancreatic market is anticipated to
grow at a CAGR between 8.0 8.6 over the
period of 2017 to 2023. Increasing global
incidences for exocrine pancreatic insufficiency
is one of the prime reasons increasing demand of
advanced therapeutics globally. Furthermore,
presence of significant number of pipeline drugs
and lipase treatment in diabetic patients,
optimizes the chymotrypsin and trypsin level are
expected to drive the global market for exocrine
pancreatic insufficiency market over the forecast
period. Moreover, the EPI market has been
segmented by the mode of disease management,
therapeutics drugs, diagnostic tests and
geography. Mode of disease management contains
nutrition management, PERT. Therapeutics drugs
consist Creon, Zenpep, Pancreaze, Ultresa and
Pertzye. Get a Sample Report _at_ https//www.infiniu
mglobalresearch.com/Reports/MakeSampleRequest/109
The report covers the analysis of exocrine
pancreatic insufficiency market by therapeutic
and diagnostic tests. Furthermore, the report
covers the analysis of global as well as regional
markets of exocrine pancreatic insufficiency.
North America dominated the global market of
exocrine pancreatic insufficiency by accounting
for the largest market share. While the Asia
Pacific region is expected to grow at a highest
CAGR over the
3

• forecast period 2017 2023. Moreover, the report
  provides deep insights on demand forecasts,
  market trends and micro and macro indicators. In
  addition, this report provides insights on the
  factors that are driving and restraining the
  demand globally as well as regionally. Moreover,
  Infinium Global Research- Growth Matrix analysis
  given in the report brings an insight on the
  investment areas that existing or new market
  players can consider.
• Company profile
• Abbvie Inc.
• Allergan plc.
• Nordmark Arzneimittel GmbH Co. KG
• Digestive Care, Inc.
• Cilian AG
• Anthera Pharmaceuticals Inc.
• Janssen Pharmaceuticals Inc.
• AzurRx BioPharma Inc.
• Make an Enquiry _at_ https//www.infiniumglobalresear
  ch.com/Reports/MakeEnquiryRequest/109 Key topics
  covered
• Preface
• Executive summary
• Exocrine pancreatic insufficiency industry
  analysis
• Exocrine pancreatic insufficiency regulatory
  aspects

4

• Exocrine Pancreatic Insufficiency Market by
  Disease Management
• Exocrine Pancreatic Insufficiency Market By
  Therapeutics Drugs
• Exocrine Pancreatic Insufficiency Market By
  Diagnosis
• Exocrine Pancreatic Insufficiency Market By
  Geography
• Company profile
• Click to View Complete Report _at_
  https//www.infiniumglobalresearch.com/healthcare_
  medical_devices/exocrine_pancreatic_insufficiency_
  market